The L’Oréal Group has announced that it has signed an agreement to acquire a majority stake in Medik8, a high-end British skincare brand. This strategic transaction is part of L’Oréal’s drive to strengthen its portfolio of luxury brands with strong international potential.
As part of the agreement between L’Oréal and Medik8, Inflexion, a major private equity player in Europe, will retain a minority stake. Elliot Isaacs, the brand’s founder, will continue to sit on the Board of Directors, while the current management team will remain in place, ensuring continuity in the brand’s vision and operations.
A brand born of science, driven by innovation
Founded by Elliot Isaacs, a scientist by training, Medik8 has made a name for itself thanks to its rigorous scientific approach and commitment to proven skincare efficacy. The brand’s flagship product, Crystal Retinal Serum, and its patented CSA Philosophy embody its unique approach to cutting-edge dermatology.
To continue reading this article, subscribe or log in to your account
Discover our plans
- Every day, keep up to date with the latest business news from the world of luxury.
- Receive the essential luxury business news by email every week
- Access all our events
- The Luxury Journals and Luxus Magazine in print and digital versions
Subscribe for 1€
Become an active member of the community of luxury leaders.
Read also > L’Oréal aims to double its business in India
Featured photo : © Medik8
